CD70
| CD70 antigen | ||
|---|---|---|
| other names |
CD27 ligand, CD27-L |
|
| Properties of human protein | ||
| Mass / length primary structure | 193 amino acids , 21,118 Da | |
| Identifier | ||
| External IDs | ||
| Orthologue (human) | ||
| Entrez | 970 | |
| Ensemble | ENSG00000125726 | |
| UniProt | P32970 | |
| Refseq (mRNA) | NM_001252.4 | |
| Refseq (protein) | NP_001243.1 | |
| PubMed search |
970
|
|
CD70 antigen (synonymous CD27 ligand , CD27L ) is a surface protein from the group of cell adhesion molecules .
properties
CD70 is involved in the activation of T cells . It induces cell proliferation and the formation of cytotoxic T cells in T cells . CD70 is glycosylated . It is also involved in the formation of germinal centers in lymph nodes and in the activation of B cells .
CD70 is involved in the development of autoimmune diseases . It is also being investigated as a target for cancer immunotherapy .
The antibody Vorsetuzumab binds to CD70 and is also being studied as a conjugate with mafodotin for the treatment of kidney cancer .
Web links
Individual evidence
- ↑ J. Denoeud, M. Moser: Role of CD27 / CD70 pathway of activation in immunity and tolerance. In: Journal of leukocyte biology. Volume 89, Number 2, February 2011, pp. 195-203, doi : 10.1189 / jlb.0610351 , PMID 20699361 .
- ↑ BK Han, NJ Olsen, A. Bottaro: The CD27-CD70 pathway and pathogenesis of autoimmune disease. In: Seminars in arthritis and rheumatism. Volume 45, number 4, February 2016, pp. 496-501, doi : 10.1016 / j.semarthrit.2015.08.001 , PMID 26359318 .
- Jump up ↑ J. Jacobs, V. Deschoolmeester, K. Zwaenepoel, C. Rolfo, K. Silence, S. Rottey, F. Lardon, E. Smits, P. Pauwels: CD70: An emerging target in cancer immunotherapy. In: Pharmacology & therapeutics. Volume 155, November 2015, pp. 1–10, doi : 10.1016 / j.pharmthera.2015.07.007 , PMID 26213107 .